טוען...
An ErbB3 antibody, MM-121, is active in cancers with ligand dependent activation
ErbB3 is a critical activator of PI3K signaling in EGFR (ErbB1), ErbB2 (HER2), and MET addicted cancers, and reactivation of ErbB3 is a prominent method for cancers to become resistant to ErbB inhibitors. In this study, we evaluated the in vivo efficacy of a therapeutic anti-ErbB3 antibody, MM-121....
שמור ב:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2840205/ https://ncbi.nlm.nih.gov/pubmed/20215504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3145 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|